Skip to main content
Erschienen in: Pathology & Oncology Research 3/2012

01.07.2012 | Research

The Effect of JDP2 and ATF2 on the Epithelial-mesenchymal Transition of Human Pancreatic Cancer Cell Lines

verfasst von: Yuanhong Xu, Zhe Liu, Kejian Guo

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic cancer is a common malignancy with a bleak outcome due to the early occurrence of micro-metastases and poor prognosis. The epithelial-mesenchymal transition (EMT) is considered to be related to the invasion and metastasis of a variety of malignant tumors. Currently, there is no research regarding the relationship of pancreatic cancer EMT with Jun dimerization protein 2 (JDP2), an inhibitor of the activator protein-1 (AP-1) family, and activating transcription factor-2 (ATF2), an AP-1-family member. In this study, we used western blot analysis and immunofluorescence to detect the protein expression of the epithelial marker E-cadherin and the mesenchymal marker vimentin in the pancreatic cancer cell line BxPC3, which was transfected with JDP2 and induced by Collagen I. Compared with the negative control, the E-cadherin and vimentin expression levels did not change significantly, whereas E-cadherin expression decreased and vimentin expression increased in the control group transfected with empty plasmid, suggesting that JDP2 inhibits the EMT induced by Collagen I. Additionally, we verified that compared with the negative control, the morphology of the Capan2 cell line induced by TGF-β1 after transfection with ATF2 was significantly changed, as was the mRNA expression of E-cadherin, whereas the mRNA expression of vimentin, Snail, and ATF2 was significantly increased. Cell invasiveness was also significantly increased (P < 0.01), suggesting that ATF2, together with TGF-β1, induced EMT in the Capan2 cell line. The members of the AP-1 family are closely related to EMT and that JDP2, as an AP-1-family inhibitor, inhibits EMT, which could lead to a new direction in molecular-targeted therapy for pancreatic cancer.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ, Cancer statistics (2006) CA Cancer J Clin 56:106–30PubMedCrossRef Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ, Cancer statistics (2006) CA Cancer J Clin 56:106–30PubMedCrossRef
2.
Zurück zum Zitat Aronheim A, Zandi E, Hennemann H, Elledge SJ, Karin M (1997) Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol Cell Biol 17:3094–102PubMed Aronheim A, Zandi E, Hennemann H, Elledge SJ, Karin M (1997) Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol Cell Biol 17:3094–102PubMed
3.
Zurück zum Zitat Heinrich R, Livne E, Ben-Izhak O, Aronheim A (2004) The c-Jun dimerization protein 2 inhibits cell transformation and acts as a tumor suppressor gene. J Biol Chem 279:5708–15PubMedCrossRef Heinrich R, Livne E, Ben-Izhak O, Aronheim A (2004) The c-Jun dimerization protein 2 inhibits cell transformation and acts as a tumor suppressor gene. J Biol Chem 279:5708–15PubMedCrossRef
4.
Zurück zum Zitat Landschulz WH, Johnson PF, McKnight SL (1988) The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240:1759–64PubMedCrossRef Landschulz WH, Johnson PF, McKnight SL (1988) The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240:1759–64PubMedCrossRef
5.
Zurück zum Zitat Glover JN, Harrison SC (1995) Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA. Nature 373:257–61PubMedCrossRef Glover JN, Harrison SC (1995) Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA. Nature 373:257–61PubMedCrossRef
6.
Zurück zum Zitat Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL (2002) p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115:3193–206PubMed Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL (2002) p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115:3193–206PubMed
7.
Zurück zum Zitat Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67:1979–87PubMedCrossRef Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67:1979–87PubMedCrossRef
8.
Zurück zum Zitat Huang TC, Kar S, Javle M (2010) Personalized therapy for pancreatic cancer: Myth or reality in 2010? J Gastrointest Oncol 1:24–33 Huang TC, Kar S, Javle M (2010) Personalized therapy for pancreatic cancer: Myth or reality in 2010? J Gastrointest Oncol 1:24–33
9.
Zurück zum Zitat Kotowski A, Ma WW (2011) Emerging therapies in pancreas cancer. J Gastrointest Oncol 2:93–103 Kotowski A, Ma WW (2011) Emerging therapies in pancreas cancer. J Gastrointest Oncol 2:93–103
10.
Zurück zum Zitat Xiao DK, He JX (2010) Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2:154–9PubMed Xiao DK, He JX (2010) Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2:154–9PubMed
11.
Zurück zum Zitat Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR (2006) Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res 66:11745–53PubMedCrossRef Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR (2006) Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res 66:11745–53PubMedCrossRef
12.
Zurück zum Zitat Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174:175–83PubMedCrossRef Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174:175–83PubMedCrossRef
13.
Zurück zum Zitat Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A (2008) HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 283:33437–46PubMedCrossRef Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A (2008) HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 283:33437–46PubMedCrossRef
14.
Zurück zum Zitat Davies M, Robinson M, Smith E, Huntley S, Prime S, Paterson I (2005) Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 95:918–31PubMedCrossRef Davies M, Robinson M, Smith E, Huntley S, Prime S, Paterson I (2005) Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 95:918–31PubMedCrossRef
15.
Zurück zum Zitat Nishioka R, Itoh S, Gui T, Gai Z, Oikawa K, Kawai M, Tani M, Yamaue H, Muragaki Y (2010) SNAIL induces epithelial-to-mesenchymal transition in a human pancreatic cancer cell line (BxPC3) and promotes distant metastasis and invasiveness in vivo. Exp Mol Pathol 89:149–57PubMedCrossRef Nishioka R, Itoh S, Gui T, Gai Z, Oikawa K, Kawai M, Tani M, Yamaue H, Muragaki Y (2010) SNAIL induces epithelial-to-mesenchymal transition in a human pancreatic cancer cell line (BxPC3) and promotes distant metastasis and invasiveness in vivo. Exp Mol Pathol 89:149–57PubMedCrossRef
16.
Zurück zum Zitat Torrisani J, Bournet B, Cordelier P (2008) Buscail L [New molecular targets in pancreatic cancer].[Article in French]. Bull Cancer 95:503–12PubMed Torrisani J, Bournet B, Cordelier P (2008) Buscail L [New molecular targets in pancreatic cancer].[Article in French]. Bull Cancer 95:503–12PubMed
17.
Zurück zum Zitat Mackenzie RP, McCollum AD (2009) Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev Anticancer Ther 9:1473–85PubMedCrossRef Mackenzie RP, McCollum AD (2009) Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev Anticancer Ther 9:1473–85PubMedCrossRef
18.
Zurück zum Zitat Furukawa T (2009) Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. Clin Gastroenterol Hepatol 7:S35–9PubMedCrossRef Furukawa T (2009) Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. Clin Gastroenterol Hepatol 7:S35–9PubMedCrossRef
19.
Zurück zum Zitat Jin C, Ugai H, Song J, Murata T, Nili F, Sun K, Horikoshi M, Yokoyama KK (2001) Identification of mouse Jun dimerization protein 2 as a novel repressor of ATF-2. FEBS Lett 489:34–41PubMedCrossRef Jin C, Ugai H, Song J, Murata T, Nili F, Sun K, Horikoshi M, Yokoyama KK (2001) Identification of mouse Jun dimerization protein 2 as a novel repressor of ATF-2. FEBS Lett 489:34–41PubMedCrossRef
20.
Zurück zum Zitat Jin C, Li H, Murata T, Sun K, Horikoshi M, Chiu R, Yokoyama KK (2002) JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to inhibit the retinoic acid-induced differentiation of F9 cells. Mol Cell Biol 22:4815–26PubMedCrossRef Jin C, Li H, Murata T, Sun K, Horikoshi M, Chiu R, Yokoyama KK (2002) JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to inhibit the retinoic acid-induced differentiation of F9 cells. Mol Cell Biol 22:4815–26PubMedCrossRef
21.
Zurück zum Zitat Jin C, Kato K, Chimura T, Yamasaki T, Nakade K, Murata T, Li H, Pan J, Zhao M, Sun K, Chiu R, Ito T, Nagata K, Horikoshi M, Yokoyama KK (2006) Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2. Nat Struct Mol Biol 13:331–8PubMedCrossRef Jin C, Kato K, Chimura T, Yamasaki T, Nakade K, Murata T, Li H, Pan J, Zhao M, Sun K, Chiu R, Ito T, Nagata K, Horikoshi M, Yokoyama KK (2006) Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2. Nat Struct Mol Biol 13:331–8PubMedCrossRef
22.
Zurück zum Zitat Yuanhong X, Feng X, Qingchang L, Jianpeng F, Zhe L, Kejian G (2010) Downregulation of AP-1 repressor JDP2 is associated with tumor metastasis and poor prognosis in patients with pancreatic carcinoma. Int J Biol Markers 25:136–40PubMed Yuanhong X, Feng X, Qingchang L, Jianpeng F, Zhe L, Kejian G (2010) Downregulation of AP-1 repressor JDP2 is associated with tumor metastasis and poor prognosis in patients with pancreatic carcinoma. Int J Biol Markers 25:136–40PubMed
23.
Zurück zum Zitat Benbrook DM, Jones NC (1990) Heterodimer formation between CREB and JUN proteins. Oncogene 5:295–302PubMed Benbrook DM, Jones NC (1990) Heterodimer formation between CREB and JUN proteins. Oncogene 5:295–302PubMed
24.
Zurück zum Zitat van Dam H, Castellazzi M (2001) Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 20:2453–64PubMedCrossRef van Dam H, Castellazzi M (2001) Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 20:2453–64PubMedCrossRef
25.
Zurück zum Zitat Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL (2003) Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 63:8103–7PubMed Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL (2003) Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 63:8103–7PubMed
26.
Zurück zum Zitat Papassava P, Gorgoulis VG, Papaevangeliou D, Vlahopoulos S, van Dam H, Zoumpourlis V (2004) Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors. Cancer Res 64:8573–84PubMedCrossRef Papassava P, Gorgoulis VG, Papaevangeliou D, Vlahopoulos S, van Dam H, Zoumpourlis V (2004) Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors. Cancer Res 64:8573–84PubMedCrossRef
27.
Zurück zum Zitat Mei Y, Yuan Z, Song B, Li D, Ma C, Hu C, Ching YP, Li M (2008) Activating transcription factor 3 up-regulated by c-Jun NH(2)-terminal kinase/c-Jun contributes to apoptosis induced by potassium deprivation in cerebellar granule neurons. Neuroscience 151:771–9PubMedCrossRef Mei Y, Yuan Z, Song B, Li D, Ma C, Hu C, Ching YP, Li M (2008) Activating transcription factor 3 up-regulated by c-Jun NH(2)-terminal kinase/c-Jun contributes to apoptosis induced by potassium deprivation in cerebellar granule neurons. Neuroscience 151:771–9PubMedCrossRef
28.
Zurück zum Zitat Lee SH, Bahn JH, Whitlock NC, Baek SJ (2010) Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene 29:5182–92PubMedCrossRef Lee SH, Bahn JH, Whitlock NC, Baek SJ (2010) Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene 29:5182–92PubMedCrossRef
Metadaten
Titel
The Effect of JDP2 and ATF2 on the Epithelial-mesenchymal Transition of Human Pancreatic Cancer Cell Lines
verfasst von
Yuanhong Xu
Zhe Liu
Kejian Guo
Publikationsdatum
01.07.2012
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2012
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9476-6

Weitere Artikel der Ausgabe 3/2012

Pathology & Oncology Research 3/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.